Thar Pharmaceuticals, Inc. (acquired by Grünenthal)
Thar Pharmaceuticals reinvents known, safe, on-the-market drugs by improving their clinical performance and economic benefits. We focus on transforming intravenous (IV) drugs into orally administered drugs, thus eliminating the cost of IV drug administration, a $34 billion annual worldwide healthcare cost paid by health systems, patients and insurers.